Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy.
Richard, Pascale PhD; Charron, Philippe MD, PhD; Carrier, Lucie PhD; Ledeuil, Celine; Cheav, Theary; Pichereau, Claire; Benaiche, Abdelaziz MD; Isnard, Richard MD; Dubourg, Olivier MD; Burban, Marc MD; Gueffet, Jean-Pierre MD; Millaire, Alain MD; Desnos, Michel MD; Schwartz, Ketty PhD; Hainque, Bernard PhD; Komajda, Michel MD; for the EUROGENE Heart Failure Project
107(17):2227-2232, May 6, 2003.
(Format: HTML, PDF)
Background-: Hypertrophic cardiomyopathy is an autosomal-dominant disorder in which 10 genes and numerous mutations have been reported. The aim of the present study was to perform a systematic screening of these genes in a large population, to evaluate the distribution of the disease genes, and to determine the best molecular strategy in clinical practice.
Methods and Results-: The entire coding sequences of 9 genes (MYH7, MYBPC3, TNNI3, TNNT2, MYL2, MYL3, TPM1, ACTC, and TNNC1) were analyzed in 197 unrelated index cases with familial or sporadic hypertrophic cardiomyopathy. Disease-causing mutations were identified in 124 index patients ([almost equal to]63%), and 97 different mutations, including 60 novel ones, were identified. The cardiac myosin-binding protein C (MYBPC3) and [beta]-myosin heavy chain (MYH7) genes accounted for 82% of families with identified mutations (42% and 40%, respectively). Distribution of the genes varied according to the prognosis (P =0.036). Moreover, a mutation was found in 15 of 25 index cases with "sporadic" hypertrophic cardiomyopathy (60%). Finally, 6 families had patients with more than one mutation, and phenotype analyses suggested a gene dose effect in these compound-heterozygous, double-heterozygous, or homozygous patients.
Conclusion-: These results might have implications for genetic diagnosis strategy and, subsequently, for genetic counseling. First, on the basis of this experience, the screening of already known mutations is not helpful. The analysis should start by testing MYBPC3 and MYH7 and then focus on TNNI3, TNNT2, and MYL2. Second, in particularly severe phenotypes, several mutations should be searched. Finally, sporadic cases can be successfully screened.
(C) 2003 American Heart Association, Inc.